Rep. Diana Harshbarger

Maddy summaryThis bill designates the U.S. Postal Service facility at 417 West 7th Street in Columbia, Tennessee, as the "Pharmacist’s Mate First Class John Harlan Willis Post Office Building." It updates all official references (including laws, maps, and documents) to reflect this new name. The bill affects the specific post office location and any federal records mentioning it, without altering postal services or creating new policies. This is a ceremonial naming bill with no substantive policy changes.

Maddy summaryThis bill renames a specific United States Postal Service facility in Knoxville, Tennessee, located at 300 Macedonia Lane, as the "Reverend Harold Middlebrook Post Office Building." It directly affects the USPS location by changing its official name and requires all federal references to the building (in laws, maps, documents, etc.) to reflect the new name. The key provision is the formal designation and updating of all official records to use the new name. This is a ceremonial naming bill with no substantive policy changes.

Maddy summaryThis bill, titled the Permanent CBDC Ban Act, aims to permanently prohibit the Federal Reserve from issuing a central bank digital currency. It achieves this by amending the Federal Reserve Act to remove the specific legal authority that allows the Reserve to create such a digital currency. The legislation directly affects the Federal Reserve by stripping away its power to launch a digital version of the dollar. By deleting the relevant subsection of the law, the bill ensures that the Reserve cannot issue a CBDC in the future.

Maddy summaryHR 4541, the EARLY Act Reauthorization of 2025, extends the funding period for the Young Women’s Breast Health Education and Awareness program. It amends the Public Health Service Act to update the program’s expiration date from 2026 to 2031. The bill directly affects young women aged 15-25 by ensuring continued access to breast health education and awareness resources. The key provision is a simple extension of the existing program’s authorization period, without altering its scope or requirements. This is a procedural reauthorization to maintain current services through 2031.

Maddy summaryThis bill requires pharmacy benefits managers (PBMs) administering prescription drug benefits for federal employee health plans to reimburse pharmacies at specific rates, including the national average drug cost plus a small percentage or $50, whichever is lower. It prohibits PBMs from favoring their own pharmacies, restricting patient choice, or reducing pharmacy payments after claims are processed. The bill establishes $10,000 civil penalties for violations, with debarment from federal health plans after 10 penalties in 10 years. This directly affects PBMs, in-network pharmacies, and federal health benefit plans covering millions of federal employees and their families. The law aims to ensure fair reimbursement practices and maintain pharmacy choice under the Federal Employees Health Benefits Program.

Maddy summaryThe Affordable Innovation for the Grid Act directs the Department of Energy to study how artificial intelligence and high-performance computing can improve the reliability and efficiency of the national power grid. This assessment will specifically examine how these technologies can speed up the process of connecting new power sources to the grid and identify any technical or cybersecurity barriers to their use. Within one year of passing, the Department of Energy must submit a report to Congress outlining its findings and offering recommendations to overcome identified limitations and encourage wider adoption of these tools. The bill primarily affects federal agencies responsible for energy oversight and the electric power industry, aiming to gather data rather than immediately changing laws.

Maddy summaryHR 4986, the Parents Opt-in Protection Act, amends federal law to require written permission before schools administer certain student surveys or evaluations. It directly affects students (especially minors) and their parents, requiring schools to obtain prior written consent from the student (if an adult or emancipated minor) or the parent (for minors) for each specific survey. The bill clarifies that schools cannot force participation without this written consent for surveys related to sensitive topics like health or behavior. This change updates existing consent rules from verbal permission to a written requirement for targeted school assessments.

Maddy summaryHR 2821, the FDA Modernization Act 3.0, requires the FDA to update regulatory language within one year of enactment. It directs the agency to replace all references to "animal tests" with "nonclinical tests" in 22 specific sections of the Code of Federal Regulations related to drug development and approval processes. The bill also adds a definition for "nonclinical test" into relevant FDA regulations to align with prior legislative changes. This update applies directly to pharmaceutical manufacturers and FDA reviewers who follow these regulatory guidelines during drug development. The changes aim to modernize terminology without altering current testing requirements.

Maddy summaryHR 1266, the Combating Illicit Xylazine Act, adds xylazine - a veterinary sedative increasingly found in illicit drug mixtures - to Schedule III of the Controlled Substances Act, regulating its use and trafficking. It directly affects veterinarians, animal owners, and manufacturers by allowing xylazine to be legally dispensed for animal use under specific veterinary prescriptions, while prohibiting non-veterinary human use. The bill includes transition periods (60 days for practitioners, 1 year for labeling) to ease compliance for manufacturers and practitioners, and requires the DEA and FDA to expedite necessary applications. It also mandates two congressional reports on xylazine's illicit use and trafficking patterns, and directs the Sentencing Commission to review penalties for offenses involving xylazine.

Maddy summaryThe TRUTH in Coverage Act of 2026 requires group health plans and health insurance issuers that cover gender-affirming procedures to also cover medical services intended to treat physical and psychological complications resulting from those procedures. This mandate applies regardless of whether the original gender-affirming treatment was covered by the plan and ensures that any required follow-up care faces the same cost-sharing rules and limitations as standard medical benefits. The bill defines "sex-rejecting procedures" broadly to include hormone therapy, surgeries, and puberty blockers, while explicitly excluding treatments for intersex conditions, life-threatening emergencies, and standard puberty suppression for early puberty. These provisions would take effect for plan years beginning on or after January 1, 2027, affecting individuals with access to employer-sponsored or individual health insurance.